Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

(FURX, CRWE, ENZ, UACL) Stock to Watch by

Stock-PR Reporting




FREE Daily Stock Alerts From






Furiex Pharmaceuticals, Inc. (Nasdaq:FURX) announced successful results from its Phase II proof-of-concept clinical trial evaluating the safety and efficacy of MuDelta, an investigational oral agent for the treatment of diarrhea-predominant irritable bowel syndrome (IBS-D). IBS-D is a common functional bowel disorder that causes chronic diarrhea and abdominal pain. MuDelta met its primary objectives of establishing tolerability, safety and efficacy in a 12-week randomized, double-blind, placebo-controlled study. The study achieved statistically and clinically significant results for its primary as well as a number of key secondary endpoints. MuDelta also demonstrated durable efficacy through the 12-week treatment period.

Read more at :